Document:

EX-4.13

 Exhibit 4.13 

Execution Version 

JOINDER AGREEMENT 
 TO

 SECOND AMENDED AND RESTATED SHAREHOLDERS AGREEMENT 

THIS JOINDER AGREEMENT TO SECOND AMENDED AND RESTATED SHAREHOLDERS AGREEMENT is made 26th
day of March, 2021 
 BETWEEN 
  

	(1)	 LianBio, an exempted company organized under the laws of the Cayman Islands (the “Company”);
and 

  

	(2)	 AEG 2021 Trust, whose trustee and beneficiary is Tom Anastasios Giannakakos (the “New
Shareholder”). 

 The Company and the New Shareholder shall be hereinafter collectively referred to as the
“Parties”. 
 WHEREAS: 
  

	(A)	 As of October 28, 2020, the Company and certain other parties identified therein entered into that certain
Second Amended and Restated Shareholders Agreement (the “Shareholders Agreement”), attached hereto as Exhibit A. 

  

	(B)	 The New Shareholder wishes to acquire an aggregate of 52,947 Series A Preferred Shares in the capital of the
Company to be issued by the Company in accordance with the terms and conditions of that certain Series A Preferred Share Subscription Agreement entered into by and between the Parties as of March 26, 2021 (the “SSA”) and has
agreed to enter into this Joinder Agreement to the Shareholders Agreement (this “Agreement”). 

  

	(C)	 The Company is entering into this Agreement on behalf of itself and as agent and trustee for all the existing
Shareholders of the Company. 

 NOW, THEREFORE, the Parties hereby agree as follows: 

 

	1.	 Interpretation. In this Agreement, except as the context may otherwise require, capitalized terms not
otherwise defined herein shall have the meanings ascribed to such terms in the Shareholders Agreement. 

  

	2.	 Covenant. The New Shareholder hereby covenants to the Company as agent and trustee for all other persons
who are at present or who may hereafter become bound by the Shareholders Agreement, and to the Company itself, to adhere to and be bound by all the duties, burdens and obligations imposed pursuant to the provisions of the Shareholders Agreement and
all documents expressed in writing to be supplemental or ancillary thereto effective as of the date of the Closing (as defined in the SSA). 

  

	3.	 Enforceability. Each existing Shareholder and the Company shall be entitled to enforce the Shareholders
Agreement against the New Shareholder, and the New Shareholder shall be entitled to all rights and benefits as an Investor under the Shareholders Agreement effective as of the date of the Closing. 

 

	4.	 Governing Law. This Agreement shall be governed by and construed under the Laws of the State of New
York, without regard to conflict of law principles that would result in the application of any Law other than the Laws of the State of New York. 

	5.	 Counterparts. This Agreement may be executed in two or more counterparts, each of which shall be deemed
an original, but all of which together shall constitute one and the same instrument. Facsimile and e-mailed copies of signatures (including PDF) shall be deemed to be originals for purposes of the
effectiveness of this Agreement. 

  

	6.	 Further Assurance. Each Party agrees to take all such further action as may be reasonably necessary to
give full effect to this Agreement on its terms and conditions. 

  

	7.	 Headings. The headings used in this Agreement are used for convenience only and are not to be considered
in construing or interpreting this Agreement. 

 [The remainder of this page has been left intentionally blank] 

 IN WITNESS whereof the Parties have executed and delivered this Agreement as a deed on the day and
year first hereinbefore mentioned. 
 COMPANY: 

LianBio 
 an exempted company organized under the laws of
the Cayman Islands 
 by the signatory specified below, being a person who in accordance with the laws of that territory is acting under the authority of the
Company 
  

			
	By:	 	 /s/ Konstantin Poukalov

		 	Name: Konstantin Poukalov
		 	Title: Director
		
	Address:	 	 LianBio
 c/o Ogier Global (Cayman) Limited

89 Nexus Way, Camana Bay
 Grand Cayman, KY1-9009, Cayman Islands

		
	Attention:	 	Konstantin Poukalov

 [Signature Page to Joinder Agreement] 

 IN WITNESS whereof the Parties have executed and delivered this Agreement as a deed on the day and
year first hereinbefore mentioned. 
 NEW SHAREHOLDER: 

AEG 2021 Trust 
 whose trustee and beneficiary is Tom
Anastasios Giannakakos 
  

			
	By:	 	 /s/ Tom Anastasios Giannakakos

		 	Name: Tom Anastasios Giannakakos
		 	Title: Trustee and Beneficiary
		
	Address:	 	 405 El Camino Real, Suite 104
 Menlo Park, CA
94025

		
	Attention:	 	Tom Anastasios Giannakakos

 [Signature Page to Joinder Agreement] 

 EXHIBIT A 

SECOND AMENDED AND RESTATED SHAREHOLDERS AGREEMENT 

 JOINDER AGREEMENT 

TO 
 SECOND AMENDED AND
RESTATED SHAREHOLDERS AGREEMENT 
 THIS JOINDER AGREEMENT TO SECOND AMENDED AND RESTATED SHAREHOLDERS AGREEMENT is made on September 15th, 2021 
 BETWEEN 
  

	(1)	 LianBio, an exempted company organized under the laws of the Cayman Islands (the “Company”);
and 

  

	(2)	 Bing Li (the “Grantee”). 

The Company and the Grantee shall be hereinafter collectively referred to as the “Parties”. 

WHEREAS: 
  

	(A)	 As of October 28, 2020, the Company and certain other parties identified therein entered into that certain
Second Amended and Restated Shareholders Agreement (the “Shareholders Agreement”), attached hereto as Exhibit A. 

  

	(B)	 The Grantee elects to exercise his option to purchase an aggregate of 224,000 Ordinary Shares of the Company
(the “Shares”) to be issued by the Company in accordance with the terms and conditions of (i) the Company’s 2019 Equity Incentive Plan (as from time to time amended and in effect, the “Plan”), (ii) certain
Share Option Grant Notice by and between the Parties as of January 1, 2020, (iii) certain Non-Statutory Stock Option Agreement by and between the Parties as of December 17, 2020, and (iv) the
Separation Agreement by and between the Parties as of February 24, 2021, and has agreed to enter into this Joinder Agreement to the Shareholders Agreement (this “Agreement”). 

 

	(C)	 The Company is entering into this Agreement on behalf of itself and as agent and trustee for all the existing
Shareholders of the Company. 

 NOW, THEREFORE, the Parties hereby agree as follows: 

 

	1.	 Interpretation. In this Agreement, except as the context may otherwise require, capitalized terms not
otherwise defined herein shall have the meanings ascribed to such terms in the Shareholders Agreement. 

  

	2.	 Acknowledgment. The Grantee acknowledges that the Grantee is acquiring the Shares as an Ordinary
Shareholder under the Shareholders Agreement, upon the terms and subject to the conditions of the Shareholders Agreement, and that such Shares will be subject to the terms of the Agreement. 

 

	3.	 Covenant. The Grantee hereby covenants to the Company as agent and trustee for all other persons who are
at present or who may hereafter become bound by the Shareholders Agreement, and to the Company itself, to adhere to and be bound by all the duties, burdens and obligations imposed pursuant to the provisions of the Shareholders Agreement and all
documents expressed in writing to be supplemental or ancillary thereto as if the Grantee has been an original party to the Shareholders Agreement since the date thereof. 

 

	4.	 Enforceability. Each existing Shareholder and the Company shall be entitled to enforce the Shareholders
Agreement against the Grantee. 

	5.	 Governing Law. This Agreement shall be governed by and construed under the Laws of the State of New
York, without regard to conflict of law principles that would result in the application of any Law other than the Laws of the State of New York. 

  

	6.	 Counterparts. This Agreement may be executed in two or more counterparts, each of which shall be deemed
an original, but all of which together shall constitute one and the same instrument. Facsimile and e-mailed copies of signatures (including PDF) shall be deemed to be originals for purposes of the
effectiveness of this Agreement. 

  

	7.	 Further Assurance. Each Party agrees to take all such further action as may be reasonably necessary to
give full effect to this Agreement on its terms and conditions. 

  

	8.	 Headings. The headings used in this Agreement are used for convenience only and are not to be considered
in construing or interpreting this Agreement. 

 [The remainder of this page has been left intentionally blank] 

 IN WITNESS whereof the Parties have executed and delivered this Agreement as a deed on the day and
year first hereinbefore mentioned. 
 COMPANY: 

LianBio 
 an exempted company organized under the laws of
the Cayman Islands 
 by the signatory specified below, being a person who in accordance with the laws of that territory is acting under the authority of the
Company 
  

			
	By:	 	 /s/ Yizhe Wang

		 	Name: Yizhe Wang
		 	Title: Director
		
	Address:	 	Harbour Place, 2nd Floor, 103 South Church Street, PO Box 472, George Town, Grand Cayman KY1-1106, Cayman Islands
		
	Attention:	 	Yizhe Wang

 [Signature Page to Joinder Agreement] 

 IN WITNESS whereof the Parties have executed and delivered this Agreement as a deed on the day and
year first hereinbefore mentioned. 
 GRANTEE: 
 Bing
Li 
  

			
	By:	 	 /s/ Bing Li

		
	Address:	 	
		
	Attention:	 	Bing Li

 [Signature Page to Joinder Agreement] 

 EXHIBIT A 

SECOND AMENDED AND RESTATED SHAREHOLDERS AGREEMENT 

 Execution Version 

JOINDER AGREEMENT 
 TO

 SECOND AMENDED AND RESTATED SHAREHOLDERS AGREEMENT 

THIS JOINDER AGREEMENT TO SECOND AMENDED AND RESTATED SHAREHOLDERS AGREEMENT is made on October 18, 2021 

BETWEEN 
  

	(1)	 LianBio, an exempted company organized under the laws of the Cayman Islands (the “Company”);
and 

  

	(2)	 Tarsus Pharmaceuticals, Inc., a Delaware corporation (“Tarsus”). 

The Company and Tarsus shall be hereinafter collectively referred to as the “Parties”. 

WHEREAS: 
  

	(A)	 As of October 28, 2020, the Company and certain other parties identified therein entered into that certain
Second Amended and Restated Shareholders Agreement (the “Shareholders Agreement”), attached hereto as Exhibit A. 

  

	(B)	 Pursuant to that certain Option Agreement dated October 18, 2021 by and between the Company and Tarsus
(the “Option Agreement”), Tarsus will acquire an aggregate of 78,373 Ordinary Shares of the Company (the “Shares”). 

  

	(C)	 The Company is entering into this Agreement on behalf of itself and as agent and trustee for all the existing
Shareholders of the Company. 

 NOW, THEREFORE, the Parties hereby agree as follows: 

 

	1.	 Interpretation. In this Agreement, except as the context may otherwise require, capitalized terms not
otherwise defined herein shall have the meanings ascribed to such terms in the Shareholders Agreement. 

  

	2.	 Acknowledgment. Tarsus acknowledges that Tarsus is acquiring the Shares as an Ordinary Shareholder under
the Shareholders Agreement, upon the terms and subject to the conditions of the Shareholders Agreement, and that such Shares will be subject to the terms of the Agreement. 

 

	3.	 Covenant. Tarsus hereby covenants to the Company as agent and trustee for all other persons who are at
present or who may hereafter become bound by the Shareholders Agreement, and to the Company itself, to adhere to and be bound by all the duties, burdens and obligations imposed pursuant to the provisions of the Shareholders Agreement and all
documents expressed in writing to be supplemental or ancillary thereto as if Tarsus has been an original party to the Shareholders Agreement since the date thereof. 

 

	4.	 Enforceability. Each existing Shareholder and the Company shall be entitled to enforce the Shareholders
Agreement against Tarsus. 

  

	5.	 Governing Law. This Agreement shall be governed by and construed under the Laws of the State of New
York, without regard to conflict of law principles that would result in the application of any Law other than the Laws of the State of New York. 

	6.	 Counterparts. This Agreement may be executed in two or more counterparts, each of which shall be deemed
an original, but all of which together shall constitute one and the same instrument. Facsimile and e-mailed copies of signatures (including PDF) shall be deemed to be originals for purposes of the
effectiveness of this Agreement. 

  

	7.	 Further Assurance. Each Party agrees to take all such further action as may be reasonably necessary to
give full effect to this Agreement on its terms and conditions. 

  

	8.	 Headings. The headings used in this Agreement are used for convenience only and are not to be considered
in construing or interpreting this Agreement. 

 [The remainder of this page has been left intentionally blank] 

 IN WITNESS whereof the Parties have executed and delivered this Agreement as a deed on the day and
year first hereinbefore mentioned. 
 COMPANY: 

LianBio 
 an exempted company organized under the laws of
the Cayman Islands 
 by the signatory specified below, being a person who in accordance with the laws of that territory is acting under the authority of the
Company 
  

			
	By:	 	 /s/ Yizhe Wang

		 	Name: Yizhe Wang
		 	Title: Chief Executive Officer
		
	Address:	 	Harbour Place, 2nd Floor, 103 South Church Street, PO Box 472, George Town, Grand Cayman KY1-1106, Cayman Islands
		
	Attention:	 	Yizhe Wang

 [Signature Page to Joinder Agreement] 

 IN WITNESS whereof the Parties have executed and delivered this Agreement as a deed on the day and
year first hereinbefore mentioned. 
 Tarsus: 

Tarsus Pharmaceuticals, Inc. 
 a Delaware corporation 

by the signatory specified below, being a person who in accordance with the laws of that territory is acting under the authority of Tarsus 

 

			
	By:	 	 /s/ Bobak Azamian

		 	 Name: Bobak Azamian
 Title: Chief Executive
Officer

		
	Address:	 	 15440 Laguna Canyon Road, Ste 160
 Irvine, CA
92618

		
	Attention:	 	Bobak Azamian

 [Signature Page to Joinder Agreement] 

 EXHIBIT A 

SECOND AMENDED AND RESTATED SHAREHOLDERS AGREEMENTEX-4.14

 Exhibit 4.14 

THIS WARRANT AND THE SECURITIES REPRESENTED BY THIS WARRANT HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”).
THESE SECURITIES HAVE BEEN ACQUIRED FOR INVESTMENT AND NOT WITH A VIEW TO, OR IN CONNECTION WITH, THE DISTRIBUTION THEREOF. THESE SECURITIES MAY NOT BE OFFERED, SOLD, PLEDGED OR TRANSFERRED UNLESS (1) A REGISTRATION STATEMENT UNDER THE ACT IS
IN EFFECT AS TO THESE SECURITIES OR (2) THERE IS AN OPINION OF COUNSEL, SATISFACTORY TO THE COMPANY, THAT AN EXEMPTION THEREFROM IS AVAILABLE. 

LIANBIO 
 WARRANT TO
PURCHASE ORDINARY SHARES 
 Issue Date: October 18, 2021 

Warrant Number: 001 
 THIS WARRANT IS TO
CERTIFY THAT, QED Therapeutics, Inc. (the “Purchaser” and, together with its nominees, successors or assigns, including any subsequent holder of this Warrant to whom it has been legally transferred, the
“Holder”) is entitled to purchase from LianBio, an exempted company organized under the laws of the Cayman Islands (the “Company”), 347,569 ordinary shares, par value US$0.000017100448 per share, of the Company
(“Ordinary Shares” and, such Ordinary Shares issuable upon exercise of this Warrant, the “Warrant Shares”), subject to adjustment in accordance with the terms hereof, at US$0.000017100448 per share (subject to
adjustment in accordance with the terms hereof, the “Exercise Price”). 
 Section 1. Exercise of Warrant. 

(a) At any time on or after the date hereof, the Holder may, at any time and from time to time but in any case prior to the tenth (10th) anniversary of the Issue Date (the “Exercise Period”), exercise this Warrant, in whole or in part in accordance with Section 1(b). 

(b) The Holder shall exercise this Warrant by means of delivering to the Company: 

 

	 	(i)	 a written Notice of Exercise in the form attached hereto as Exhibit A, which shall include the number of
Warrant Shares to be delivered pursuant to such exercise (the “Notice of Exercise”); 

  

	 	(ii)	 this Warrant; and 

  

	 	(iii)	 payment equal to the Exercise Price by cash, certified check to the order of the Company or wire transfer of
immediately available funds to an account specified by the Company. 

 (c) Upon exercise of this Warrant in accordance with
Section 1(b), the Company shall cause the Warrant Shares issuable upon such exercise to be registered in the name of the Holder or such other name or names as may be designated in the Notice of Exercise in the books of the
Company. In case such exercise is in part only, the Company shall cause to be executed and delivered to the Holder a new warrant or warrants (dated the date hereof) of like tenor, calling in the aggregate on the face or faces thereof for the number
of Warrant Shares equal to the number of such Warrant Shares described in this Warrant minus the number of such Warrant Shares purchased by the Holder upon all exercises made in accordance with this Section 1. 

(d) The Warrant Shares shall be deemed to have been issued, and the Holder or any other person so designated to be named therein shall be
deemed to have become the holder of record of such shares (including to the extent permitted by law the right to vote such shares or to consent or to receive notice as stockholders), upon the delivery of all deliverables set forth in
Section 1(b). 

 (e) The Holder shall be responsible for all transfer taxes resulting from the fact that any
certificate issued in respect of Warrant Shares is not in the name of the Holder. 
 (f) All Warrant Shares issuable upon the exercise of
this Warrant in accordance with the terms hereof shall be validly issued, fully paid and non-assessable, and free from all liens and other encumbrances thereon, other than liens or other encumbrances created
by the Holder or restrictions upon transfer under federal or state securities laws. 
 (g) During the Exercise Period, the Company shall at
all times reserve and keep available out of its authorized but unissued Ordinary Shares, solely for the purpose of issuance upon the exercise of this Warrant, the maximum number of Warrant Shares issuable upon the exercise of this Warrant, and the
par value per Warrant Share shall at all times be less than or equal to the applicable Exercise Price. The Company shall not increase the par value of any Warrant Shares receivable upon the exercise of this Warrant above the Exercise Price then in
effect, and shall take all such actions as may be necessary or appropriate in order that the Company may validly and legally issue fully paid and nonassessable Ordinary Shares upon the exercise of this Warrant. 

(h) In no event shall any fractional Warrant Share be issued upon exercise of this Warrant. If, upon exercise of this Warrant, the Holder
would, except as provided in this paragraph, be entitled to receive a fractional Warrant Share, then the Company shall, at the Company’s sole discretion, either (i) deliver in cash to such holder an amount equal to such fractional
interest, or (ii) issue a whole share in lieu of such fractional share. 
 Section 2. Adjustment of Exercise Price and Warrant
Shares. 
 (a) Subdivision or Combination of Ordinary Shares. If, at any time during the Exercise Period, the number of
outstanding Ordinary Shares is (i) increased by a share dividend payable in Ordinary Shares or by a subdivision or split-up of Ordinary Shares, or (ii) decreased by a combination of Ordinary Shares,
then, following the record date fixed for the determination of holders of Ordinary Shares entitled to receive the benefits of such share dividend, subdivision, split-up, or combination, the Exercise Price
shall be adjusted to a new amount equal to the product of (A) the Exercise Price in effect on such record date, and (B) the quotient obtained by dividing (x) the number of Warrant Shares into which this Warrant would be exercisable on
such record date (without giving effect to the event referred to in the foregoing clause (i) or (ii)), by (y) the number of Warrant Shares which would be outstanding immediately after the event referred to in the foregoing clause
(i) or (ii), if this Warrant had been exercised immediately prior to such record date. 
 (b) Adjustment to Warrant Shares. Upon
each adjustment of the Exercise Price as provided in Section 2(a), the Holder shall thereafter be entitled to subscribe for and purchase, at the Exercise Price resulting from such adjustment, the number of Warrant Shares
equal to the product of (i) the number of Warrant Shares into which this Warrant would be exercisable prior to such adjustment and (ii) the quotient obtained by dividing (A) the Exercise Price existing prior to such adjustment by
(B) the new Exercise Price resulting from such adjustment. 
 Section 3. Reclassification, Merger, Consolidation, Etc. 

In case of any reclassification or change of the outstanding Ordinary Shares (other than as a result of a subdivision, combination or share
dividend), or in case of any consolidation of the Company with, or merger of the Company into, another corporation or other business organization (other than a consolidation or merger in which the Company is the surviving entity) at any time during
the Exercise Period, then the Company or its successor may make lawful and adequate provision to 

  
 - 2 - 

 
grant the Holder the right to purchase, upon exercise of this Warrant, the kind and amount of shares and other securities and property receivable upon such reclassification, reorganization,
change, consolidation or merger by a holder of the number of Warrant Shares of the Company which might have been purchased by the Holder immediately prior to such reclassification, reorganization, change, consolidation or merger, at a total price
not to exceed that payable upon the exercise of this Warrant, and, in any such case, appropriate provisions shall be made with respect to the rights and interest of the Holder such that the provisions hereof shall thereafter be applicable in
relation to any shares and other securities and property thereafter deliverable upon exercise hereof. 
 Section 4. Rights of
Shareholders. 
 Nothing contained herein shall be construed to confer upon the Holder, as such, any of the rights of a shareholder of
the Company or any right to vote for the election of directors or upon any matter submitted to shareholders at any meeting thereof, or to give or withhold consent to any corporate action (whether upon any recapitalization, issuance of shares,
reclassification of shares, change of par value or change of shares to no par value, consolidation, merger, conveyance, or otherwise) or to receive notice of meetings, or to receive dividends or subscription rights or otherwise until the Warrant
shall have been exercised and the certificates representing the Warrant Shares shall have been issued, as provided herein. 

Section 5. Share and Warrant Books. 

The Company will not at any time, except upon dissolution, liquidation or winding up, close its share books or warrant books so as to result
in preventing or delaying the exercise of any Warrant. 
 Section 6. Limitation of Liability. 

No provisions hereof, in the absence of affirmative action by the Holder to purchase Warrant Shares hereunder, shall give rise to any
liability of the Holder to pay the Exercise Price or as a shareholder of the Company (whether such liability is asserted by the Company or creditors of the Company). 

Section 7. Transfer Restrictions 

(a) Generally. This Warrant shall not be transferrable by the Holder to any third party without the prior written approval of the
Company; provided, that subject to Section 7(b), the Holder may transfer this Warrant to any person or entity that directly or indirectly is controlled by or controls the Holder (an “Affiliate”), in each
case where the term “control” means possession, directly or indirectly, of the power to direct or cause the direction of the management and policies of an entity, whether through ownership of a majority of voting securities, by contract or
otherwise. 
 (b) Repurchase Right. In the event the Holder proposes to transfer this Warrant in accordance with
Section 7(a) to an Affiliate that becomes an Affiliate of the Holder as a result of a Change of Control of the Holder, the Holder shall give the Company prior written notice of the Holder’s intention to make such
transfer (the “Transfer Notice”), which notice shall include the identity and address of the proposed transferee Affiliate. Within thirty (30) Business Days following the receipt of the Transfer Notice, the Company shall have
an option to, by written notice to the Holder (the “Exercise Notice”), repurchase the Warrant at a price equal to the product of: (i) the Fair Market Value (as defined below) per Ordinary Share as of the date of the Exercise
Notice, (ii) the number of Warrant Shares issuable upon exercise of this Warrant (or, if only a portion of this Warrant is being exercised, issuable upon the exercise of such portion) for cash, determined as provided in
Section 2, and (iii) a fraction, the numerator of which is the Fair Market Value per Ordinary Share at the time of such exercise minus the Exercise Price in effect at the time of such exercise, and the
denominator of which is the Fair Market Value per Ordinary Share at the time of such exercise, such number of shares so issuable upon such exercise to be rounded up or down to the nearest whole 

  
 - 3 - 

 
number of Ordinary Shares. “Fair Market Value” means (a) if the Ordinary Shares are not traded on a securities exchange, the fair market value of an Ordinary Share, as
determined in good faith by the board of directors of the Company and (b) if the Ordinary Shares are traded on a securities exchange, the average of the closing bid or sales price (whichever is applicable) over the thirty (30) day period
ending three days before the relevant date of the valuation. “Change of Control” means, with respect to an entity, (i) a merger or consolidation of such entity with a third party that is not an Affiliate of such entity, which
results in the voting securities of such entity outstanding immediately prior thereto, or any securities into which such voting securities have been converted or exchanged, ceasing to represent more than fifty percent (50%) of the combined voting
power of the surviving entity or the parent of the surviving entity immediately after such merger or consolidation, (ii) a transaction or series of related transactions in which a third party that is not an Affiliate of such entity, together
with Affiliates of such third party, becomes the direct or indirect beneficial owner of more than fifty percent (50%) of the combined voting power of the outstanding securities of such entity, or (iii) the sale or other transfer to a third
party that is not an Affiliate of such entity of all or substantially all of such entity’s and its controlled Affiliates’ assets. Notwithstanding the foregoing, any transaction or series of transactions effected for the primary purpose of
financing the operations of the applicable entity (including the issuance or sale of securities for financing purposes), or changing the form or jurisdiction of organization of such entity will not be deemed a “Change of Control” for
purposes of this Warrant. 
 Any Warrants issued upon the transfer of this Warrant shall be numbered and shall be registered in a Warrant
register as they are issued. The Company shall be entitled to treat the registered holder of any Warrant on the Warrant register as the owner in fact thereof for all purposes and shall not be bound to recognize any equitable or other claim to, or
interest in, such Warrant on the part of any other person, and shall not be liable for any registration of transfer of Warrants that are registered or to be registered in the name of a fiduciary or the nominee of a fiduciary unless made with the
actual knowledge that a fiduciary or nominee is committing a breach of trust in requesting such registration or transfer, or with the knowledge of such facts that its participation therein amounts to bad faith. This Warrant shall be transferable
only on the books of the Company upon delivery thereof duly endorsed by the Holder or by its duly authorized attorney or representative, or accompanied by proper evidence of succession, assignment, or authority to transfer. In all cases of transfer
by an attorney, executor, administrator, guardian, or other legal representative, duly authenticated evidence of his or its authority shall be produced. Upon any registration of transfer, the Company shall deliver a new Warrant or Warrants to the
person entitled thereto. Notwithstanding the foregoing, the Company shall have no obligation to cause Warrants to be transferred on its books to any person if, in the opinion of counsel to the Company, such transfer does not comply with the
provisions of the securities laws, rules and regulations of the applicable jurisdictions. 
 Section 8. Investment Representations;
Restrictions on Warrant Shares. 
 The Holder covenants and agrees that this Warrant is acquired for the account of the Holder and is
not acquired with a view to, or for sale in connection with, any distribution thereof (or any portion thereof) and with no present intention (at any such time) of offering and distributing such securities (or any portion thereof). 

Section 9. Loss, Destruction of Warrant Certificates. 

Upon receipt of evidence satisfactory to the Company of the loss, theft, destruction or mutilation of this Warrant and, in the case of any
such loss, theft or destruction, upon receipt of indemnity and/or security satisfactory to the Company or, in the case of any such mutilation, upon surrender and cancellation of such Warrant, the Company will make and deliver, in lieu of such lost,
stolen, destroyed or mutilated Warrant, a new Warrant of like tenor and representing the right to purchase the same aggregate number of Warrant Shares. 

  
 - 4 - 

 Section 10. Amendments. 

The terms of this Warrant may be amended, and the observance of any term herein may be waived, with the prior written consent of the Company
and the Holder. 
 Section 11. Notices Generally. 

All notices, deliveries and other communications given or made pursuant to the provisions hereof shall be in writing and shall be deemed
effectively given: (a) upon personal delivery to the party to be notified, (b) when sent by confirmed electronic mail or facsimile if sent during normal business hours of the recipient, and if not so confirmed, then on the next business
day, (c) five (5) days after having been sent by registered or certified mail, return receipt requested, postage prepaid, or (d) two (2) business days after deposit with an internationally recognized overnight courier, specifying next
business day delivery, with written verification of receipt. All communications shall be sent to the respective parties at their address as set forth on the signature page, or to such e-mail address, facsimile
number or address as subsequently modified by written notice to the other party. 
 Section 12. Successors and Assigns. 

This Warrant shall bind and inure to the benefit of and be enforceable by the parties hereto and their respective permitted successors and
assigns. 
 Section 13. Governing Law. 

In all respects, including all matters of construction, validity and performance, this Warrant and the obligations arising hereunder shall be
governed by, and construed and enforced in accordance with the laws of the Cayman Islands, without giving effect to any choice of law rule that would cause the application of the laws of any other jurisdiction. 

Section 14. Dispute Resolution. 

(a) Any dispute, controversy or claim (each, a “Dispute”) arising out of or relating to this Warrant, or the interpretation,
breach, termination, validity or invalidity thereof, shall be settled by the parties amicably through good faith discussions upon the written request of any party. In the event the Dispute is not resolved thereby within a period of thirty
(30) days after such request has been given, such Dispute shall be referred to and conclusively determined by arbitration upon the demand of any party to the dispute with notice (the “Arbitration Notice”) to the other party or
parties. 
 (b) The Dispute shall be settled by arbitration in Hong Kong by the Hong Kong International Arbitration Centre (the
“HKIAC”) in accordance with the Hong Kong International Arbitration Centre Administered Arbitration Rules (the “HKIAC Rules”) in force when the Arbitration Notice is submitted in accordance with the HKIAC Rules.

 (c) The disputing parties may jointly select one (1) arbitrator, or agree that the Chairman of HKIAC shall select the arbitrator. In
the absence of such agreement, there shall be three (3) arbitrators, the claimant to the Dispute, or in the case of multiple claimants, all such claimants acting collectively (the “Claimant”) shall select one
(1) arbitrator and the respondent to the Dispute, or in the case of more than one respondent, the respondents acting collectively (the “Respondent”) shall select one (1) arbitrator. All selections shall be made within
thirty (30) days after the selecting party gives or receives the demand for arbitration. Such arbitrators shall be freely selected, and neither the Claimant nor the Respondent shall be limited in their selection to any prescribed list. The
Chairman of HKIAC shall select the third arbitrator who will act as chair of the arbitration board. If any arbitrator to be appointed by a party has not been appointed and consented to participate within thirty (30) days after the selection of
the first arbitrator, the relevant appointment shall be made by the Chairman of HKIAC. 

  
 - 5 - 

 (d) The arbitral proceedings shall be conducted in English. To the extent that the HKIAC
Rules are in conflict with the provisions of this Section 14, including the provisions concerning the appointment of the arbitrators, the provisions of this Section 14 shall prevail. 

(e) Each party to the arbitration shall cooperate with each other party to the arbitration in making full disclosure of and providing complete
access to all information and documents requested by such other party in connection with such arbitral proceedings, subject only to any confidentiality obligations binding on such party. 

(f) The award of the arbitral tribunal shall be final and binding upon the parties thereto, and the prevailing party may apply to a court of
competent jurisdiction for enforcement of such award. 
 (g) The arbitral tribunal shall decide any Dispute submitted by the parties to the
arbitration strictly in accordance with the substantive laws of the Cayman Islands (without regard to principles of conflict of laws thereunder) and shall not apply any other substantive law. 

(h) Any party to the Dispute shall be entitled to seek preliminary injunctive relief, if possible, from any court of competent jurisdiction
pending the constitution of the arbitral tribunal. 
 (i) During the course of the arbitral tribunal’s adjudication of the Dispute, the
terms and provisions of this Warrant shall continue to be performed except with respect to the part in dispute and under adjudication. 

Section 15. Waiver and Release 

The parties hereto hereby acknowledge and agree that this Warrant is issued in lieu, and in full settlement, of the Equivalent Lian Shares (as
defined in the Option Agreement (as defined below)) and that the issuance of this Warrant is expressly contingent upon the Purchaser’s waiver of, and the Purchaser hereby expressly waives, any and all rights and claims it may have under the
Option Agreement, including without limitation with respect to the Equivalent Lian Shares or any other equity securities of the Company arising from or in connection with the Option Agreement. The Purchaser hereby acknowledges and agrees that those
certain warrants issued as of October 16, 2019, by Lian Oncology, a wholly-owned subsidiary of the Company to the Purchaser with warrant numbers of A-1, A-2 and A-3 are hereby irrevocably terminated and deemed void ab initio. 
 “Option
Agreement” means the Amended and Restated Option Agreement dated as of August 10, 2020, by and among the Purchaser, the Company, and certain other parties as set forth thereof. 

[The remainder of this page has been left intentionally blank] 

  
 - 6 - 

 IN WITNESS WHEREOF, the Company has caused this Warrant to be signed in its name by
its duly authorized officer. 
  

					
	 LIANBIO
  

 
 By: /s/ Yizhe
Wang                                         
                           

Name: Yizhe Wang
 Title: Chief Executive Officer
	 		  	 LianBio
 c/o Travers Thorp Alberga

Harbour Place, 2nd Floor
 PO Box 472

103 South Church Street
 Grand Cayman, KY1-1106, Cayman Islands
 Attention: Yizhe Wang, Chief Executive Officer

			
		 		  	 With copies to:
  

Ropes & Gray LLP
 36F Park Place

1601 Nanjing Road West
 Shanghai, China 200040

Attention: Eric Wu
 Fax:

Email:

 [Signature Page to Warrant] 

 AGREED AND ACCEPTED: 
  

			
	QED THERAPEUTICS, INC.	  	 Address:
 75 Federal Street

San Francisco, CA 94107

		
	 By: /s/ Neil
Kumar                                        
                                    

Name: Neil Kumar
 Title: President
	  	

 [Signature Page to Warrant] 

 EXHIBIT A 

NOTICE OF EXERCISE

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00335-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00335-of-00352.parquet"}]]